The mechanisms by which tumour cells metastasize and the role that cell polarity proteins play in this process are not well understood. We report that partitioning defective protein 3 (Par3) is dysregulated in metastasis in human breast cancer, and is associated with a higher tumour grade and ErbB2-positive status. Downregulation of Par3 cooperated with ErbB2 to induce cell invasion and metastasis in vivo. Interestingly, the metastatic behaviour was not associated with an overt mesenchymal phenotype. However, loss of Par3 inhibited E-cadherin junction stability, disrupted membrane and actin dynamics at cell-cell junctions and decreased cell-cell cohesion in a manner dependent on the Tiam1/Rac-GTP pathway. Inhibition of this pathway restored E-cadherin junction stability and blocked invasive behaviour of cells lacking Par3, suggesting that loss of Par3 promotes metastatic behaviour of ErbB2-induced tumour epithelial cells by decreasing cell-cell cohesion.
The partitioning defective (Par) family of cell polarity proteins, Par-1, Par-3 (Pard3), Par-4, Par-5 and Par-6, were identified in Caenorhabditis elegans as regulators of asymmetric cell division during early embryonic development [1] [2] [3] . In mammals, Par proteins including Par1b (EMK1/MARK2), Par3, Par4 (LKB1), 14-3-3 (Par5), Par6 and protein kinase C ι/ζ (atypical PKC, aPKC), facilitate the generation of intracellular asymmetry and regulate various processes such as the establishment of apical-basal polarity, directional cell migration and asymmetric cell division 4 . Although the precise mechanism by which Par proteins regulate these biological processes remains to be understood, it involves a coordinated regulation of protein localization and actin/microtubule cytoskeletal dynamics 5 . Very little is known about the pathways that regulate the loss of cell and tissue architecture in carcinoma; however, emerging evidence points to a direct role for Par proteins as important regulators 6 . We demonstrated that erythroblastic leukaemia viral oncogene homologue 2 (ErbB2; also referred to as human epidermal growth factor receptor 2, HER2) interacts with the Par6-aPKC complex and that this interaction is required during ErbB2-induced disruption of apical-basal polarity and transformation of polarized epithelial cells 7 . Par6 is also a critical mediator of transforming growth factor-β (TGF-β)-induced epithelial to mesenchymal transition (EMT) and metastasis 6 . It has been demonstrated that Par6 and aPKC are overexpressed and/or amplified in breast, ovarian and lung cancers [8] [9] [10] and the genomic region containing the Pard3 gene is deleted in lung, head and neck and oesophageal squamous cell carcinoma cell lines 11, 12 . The Par complex member Par3 is a signalling scaffold that contains three PSD-95/Discs-large/ZO-1 (PDZ) domains, an aminoterminal dimerization domain and a carboxy-terminal aPKCinteraction domain 4, 13 . The PDZ domains interact with cell surface proteins such as junctional adhesion molecules 14 and nectin 15 , cytoplasmic proteins Par6 (ref. 6) , phospholipids (PIP2) and the phosphatase and tensin homologue [16] [17] [18] (PTEN). The Cterminal domain of Par3 interacts with aPKC to inhibit its kinase activity 19, 20 and with a Rac1 GTPase-specific GTP exchange factor Tiam1 (T lymphoma invasion and metastasis) to inhibit its exchange activity 21 . Whereas the Par3-aPKC interaction regulates establishment of the apical membrane, Par3-Tiam1 interaction is sufficient for tight junction biogenesis 22 . A similar Par3-Tiam1-dependent, but aPKC-independent, interaction is also required during dendritic spine morphogenesis 23 . Expression of dominant-negative Rac or downregulation of Tiam1 rescued the Par3 loss phenotype, demonstrating that the ability of Par3 to inhibit Rac activation plays an important role during dendritic spine morphogenesis. Here, we report our findings on the role Par3 plays during metastasis of breast cancer. 
RESULTS

Loss of Par3 cooperates with ErbB2 to induce invasive behaviour in mammary epithelial cells
We designed two independent short hairpin RNAs (shRNAs) targeting Par3 (Fig. 1a) and generated stable populations of MCF-10A cells expressing an inducible form of the oncogenic receptor tyrosine kinase ErbB2 (10A.B2; ref. 24 ). Par3 shRNA-B was shown to be the most efficient shRNA and was used in the further experiments. Activation of ErbB2 in both GFP-and Par3-shRNA cells disrupted normal three-dimensional acinar morphogenesis and induced the formation of multi-acinar structures when grown in Matrigel (Fig. 1b,c) . Interestingly, 17% of multi-acinar structures derived from Par3-shRNA cells showed evidence of loose cell-cell adhesions and invasive protrusions (Fig. 1b, lower panel, c) . Consistent with invasive protrusions (Supplementary Fig. S1 ), activation of ErbB2 induced a significant increase in invasion of Par3-shRNA cells when compared with GFP-shRNA cells (30-fold versus 5-fold increase respectively; Fig. 1d ) in Transwell invasion assays. Both GFP-and Par3-shRNA cells showed an increase in proliferation in response to ErbB2 activation as monitored by Ki-67 expression (Fig. 1e) . Acini derived from Par3-shRNA cells, in the absence of ErbB2 activation, showed increased proliferation when compared with GFP-shRNA cells (Fig. 1e) , consistent with recent observations in mouse mammary epithelial cells 25 where loss of Par3 induced an increase in cell proliferation. However, loss of Par3, in the absence of ErbB2 activation, was not sufficient to induce multi-acinar structures (Fig. 1b) .
In addition to MCF-10A cells, we knocked down Par3 in T47D and SKBR3 cells (Fig. 1f) . Both T47D and SKBR3 cells expressing Par3 shRNA showed a significant increase in invasive ability in Transwell invasion assays (Fig. 1g) . Thus, loss of Par3 induced invasion both in ErbB2-transformed MCF-10A cells and in cell lines derived from human breast tumours.
Downregulation of Par3 promotes metastasis of primary mouse mammary tumours in vivo
To determine whether downregulation of Par3 induces metastasis in vivo, we generated lentiviral shRNAs targeting mouse Par3 (Fig. 2a) . Primary tumour epithelial cells were isolated from transgenic mice expressing a Neu/ErbB2 deletion mutant (NDL; an extracellular domain mutant that promotes constitutive receptor dimerization) under the control of the mouse mammary tumour virus (MMTV) long terminal repeat 26 (LTR). Cells were infected with a control virus or mouse Par3 (mPar3) shRNA co-expressing enhanced green fluorescent protein (EGFP) as a reporter for infected cells. Infected, but not selected, cells were transplanted into pre-cleared mammary fat pads of NOD/SCID mice. Both vector-and mPar3-shRNA-infected cells developed GFP-positive tumours with the same latency. One cohort of mice was euthanized 12 weeks after transplantation when the tumour size reached 1.5 cm diameter. In the second cohort of mice, the primary tumour nodes were removed at week six to relieve the tumour burden and the mice were maintained for 14-18 more weeks (Fig. 2b) . The primary tumours generated by mPar3-shRNA-infected cells or vector-infected cells did not differ significantly in total mass or their histology (Fig. 2c,d ). mPar3-shRNA-infected cells developed significantly more GFP-positive lung metastases (5 out of 10) when compared with the lung metastases in vector-infected group (1 out of 10; Fig. 2e , P = 0.008). Primary tumours and metastases from both vector and mPar3 shRNA had epithelial morphology and expressed E-cadherin at cell-cell contacts and mPar3-shRNA-derived primary tumours and metastases had downregulation of Par3 expression (n = 3; Fig. 2d-f ). In addition, loss of Par3 also promoted local invasion of transplanted tumour cells (see Supplementary Fig. S2 for details). Thus, loss of Par3 was sufficient to initiate metastatic behaviour in epithelial cells derived from ErbB2-induced primary mouse mammary tumours.
Acquisition of invasive behaviour is frequently associated with EMT. However, activation of ErbB2 did not induce morphological changes associated with EMT in either GFP-or Par3-shRNA cells (Fig. 2g) . However, stimulation of both GFP-and Par3-shRNA cells with TGF-β, a known promoter of EMT, induced a loss of epithelial morphology and acquisition of spindle-shaped mesenchymal morphology (Fig. 2g , right panel). Consistent with the lack of changes in cell morphology, the expression of mesenchymal markers such as snail, N-cadherin and fibronectin was not altered by loss of Par3 in either 10A.B2 or T47D cells (Fig. 2h,i ). We note that there was a modest increase in the level of fibronectin expression (less than 5-fold), which was low when compared with the more than 800-fold increase in the expression level observed in response to TGF-β (Fig. 2h ). In addition, loss of Par3 did not decrease the expression level of the epithelial marker E-cadherin in 10A.B2, T47D or BT474 cells (Fig. 2j) . We also did not observe obvious differences in E-cadherin localization in confluent monolayers of epithelial cells (Fig. 2k ) or tumours derived from Par3-shRNA cells (Fig. 2d ). These observations suggest that loss of Par3 cooperates with ErbB2 to induce invasive behaviour in epithelial cells without being associated with an overt EMT.
Loss of Par3 decreases cell-cell cohesion
To understand the mechanism by which loss of Par3 induces invasion, we monitored ErbB2-induced changes in MCF-10A cell behaviour in monolayers. Dividing Par3-shRNA daughter cells failed to stay cohesive within a colony, whereas GFP-shRNA daughters remained proximal to each other within an epithelial island (Fig. 3a) , suggesting a decrease in the level of cell-cell cohesion. To determine whether this decrease in cohesiveness is due to increased motility promoted by integrin-mediated signalling 27 , GFP-and Par3-shRNA cells were plated on Matrigel-coated coverslips in the absence or presence of ErbB2 activation (Fig. 3b) . The cells did not differ in their ability to adhere and spread on a Matrigel-coated surface, demonstrating that loss of Par3 did not activate integrin-mediated functions. To determine whether loss of Par3 affects cell-cell interactions, we performed a cell aggregation assay by suspending cells in drops of media hanging from the lid of a culture dish. Activation of ErbB2 in GFP-shRNA cells induced a decrease in the number of cell clumps (Fig. 3c,d ), indicating weakened cell cohesiveness, which is consistent with previous reports showing that activation of ErbB2 can induce a decrease in E-cadherin function 28 . Par3-shRNA cells, in the absence of ErbB2 activation, decreased the number of clumps and activation of ErbB2 induced dispersal of all large clumps in Par3-shRNA cells (Fig. 3c,d ).
E-cadherin-based adherens junctions (herein referred to as Ecadherin junctions) are the primary mediators of cell-cell interaction in epithelial cells and disruption of E-cadherin junctions is known to induce cell scattering. Activation of ErbB2 induced scattering of Par3-shRNA, but not the control GFP-shRNA cells (Fig. 3e , phase images in Supplementary Fig. S3a ) and neither GFP-nor Par3-shRNA cells scattered in the absence of ErbB2 activation. Interestingly, GFP-shRNA cells exposed to an E-cadherin neutralizing antibody 29 (HECD-1) scattered on ErbB2 activation ( Fig. 3f and Supplementary  Fig. S3b ), demonstrating that cell scattering in the Par3-depleted cells is due to a combined effect of weakened E-cadherin junctions and activation of ErbB2.
Par3 is required for E-cadherin junction stability
We investigated whether Par3 regulates functional properties of E-cadherin junctions. During the formation of E-cadherin junctions, nascent junctions are unstable and have E-cadherin molecules that constantly recycle at junctions. In contrast, mature junctions are stable and have a high fraction of immobile E-cadherin in MDCK cell monolayers 30, 31 . 10A.B2 cells expressing E-cadherin-GFP were subjected to a calcium switch assay and E-cadherin at cell-cell contacts was monitored by fluorescence recovery after photobleaching (FRAP). One hundred per cent of E-cadherin was recovered within five minutes after photobleaching at t = 0, whereas only 87 and 64% of E-cadherin was recovered at 60 min and 120 min after the calcium switch assay respectively, demonstrating that the percentage of the immobile fraction of E-cadherin increased as cell-cell junctions mature (Fig. 3g) .
FRAP analysis in established junctions revealed that only 56% of the GFP signal was recovered in control cells, whereas 88% of the GFP signal was recovered in Par3-shRNA cells, demonstrating that only 12% of the E-cadherin junctions were immobile in cells lacking Par3 (Fig. 3h,i ). These observations demonstrate that E-cadherin junctions were labile in mammary epithelial cells lacking Par3.
Loss of Par3 activates Tiam1-Rac signalling
Par3 is known to interact with Tiam1 and inhibit its guanine nucleotide exchange activity towards Rac GTPase (ref. 22) . Although Rac activity is required for E-cadherin junction formation 32 , constitutive activation of Rac induces disruption of E-cadherin junctions by promoting aberrant actin remodelling 33, 34 . To monitor changes in Tiam1 activation and Rac-GTP levels in Par3-shRNA cells we used Rac1 G15A, a nucleotidefree Rac1 mutant that interacts with active Tiam1 (refs 35,36) , and p21-activated kinase (PAK)-binding domain (PAK-PBD)-pulldown assays 37 . Cells lacking Par3 had a marked increase in the levels of active Tiam1 (Fig. 4a ) and high Rac-GTP levels under unstimulated conditions when compared with the levels present in GFP-shRNA cells (Fig. 4b, comparing lanes 1 and 5) . Activation of ErbB2 induced a fourfold increase in the Rac-GTP levels in GFP-shRNA cells (Fig. 4b) , similar to the levels observed in Par3-shRNA irrespective of ErbB2 activation. In contrast, loss of Par3 did not have any effect on either basal or ErbB2-induced Ras/mitogen activated protein kinase (MAPK) activation or the ErbB2-activated AKT pathway (Fig. 4c) . To monitor changes in the spatial distribution of Rac-GTP activation in Par3-shRNA cells, we used Förster resonance energy transfer (FRET) with the Raichu-Rac biosensor. The localization of Raichu-Rac fusion monitored using a CFP image is different from endogenous Rac and is known to be related to local GEF activity 38 . Raichu-Rac was mainly localized to cell-cell junctions in GFP-shRNA cells, whereas it showed a diffuse distribution in the cytosol in Par3-shRNA cells (Fig. 4d) . On ErbB2 activation, Rac-GTP loading was focally increased at cell-cell junctions in GFP-shRNA cells, whereas Rac-GTP loading was diffusely elevated throughout the cytosol in Par3-shRNA cells ( Fig. 4d and Supplementary Fig. S4a ). These observations demonstrate that Par3 is required for spatial control of Rac-GTP activation in mammary epithelial cells.
Contribution of Tiam1-Rac and ErbB2 signalling to
Par3-loss-induced cell invasion and E-cadherin junction stability Downregulation of Tiam1 (Fig. 5a ) efficiently inhibited ErbB2-induced invasion in Par30-shRNA cells (Fig. 5b) , demonstrating that increased Tiam1 activity in Par3-shRNA cells is required for cell invasion. In addition, we generated Flag-tagged RNAi-resistant Par3 full-length (Par3-FL) and a truncated mutation lacking the C terminus, which cannot bind to Tiam1 (ref. 22; Par3-C; Fig. 5c,d) . Expression of Par3-FL was able to inhibit Par3-loss-induced cell invasion, whereas Par3-C failed to rescue the Par3-loss phenotype (Fig. 5e) . Furthermore, stable expression of dominant-negative Tiam1 (Supplementary Fig. S4b ), a mutant of Tiam1 that contains the N-terminal pleckstrin homology domain, the proximal coiled-coil and the adjacent Ex domain (Tiam1-PHn-CC-Ex; ref. 39 and Supplementary Fig. S4b ), inhibited the formation of Par3-shRNA acini with compromised margins (Supplementary Fig. S4c ) and decreased the ability of Par3-shRNA cells to invade through Matrigel (Supplementary Fig. S4d ). Last, we tested the effects of the compound NSC23766, an inhibitor that interferes with binding of Rac to Tiam1 or TrioN GEFs (ref. 40 ). Treatment of Par3-shRNA cells with NSC23766 at concentrations sufficient to decrease the high basal levels of Rac-GTP observed in Par3-shRNA The cells treated with inhibitors were subjected to a Transwell invasion assay (mean ± s.e.m., n = 3; j) and E-cadherin FRAP analysis (sample sizes are listed below the graph; k) as described above. Uncropped images of blots are shown in Supplementary Fig. S7 .
cells (Fig. 5f ) inhibited ErbB2-induced cell invasion (Fig. 5g ) and cell scattering ( Supplementary Fig. S4e) . Thus, the Tiam1-Rac pathway was required for Par3-shRNA-induced cell invasion.
To determine whether dysregulation of Tiam1-Rac.GTP is required for changes in the E-cadherin junction, Par3-shRNA/E-cadherin-GFP cells were treated with NSC23766 and subjected to FRAP analysis. Whereas treatment of the parental 10A.B2 cells with NSC23766 did not change the percentage of immobile fraction of E-cadherin, treatment of Par3-shRNA cells induced a more than twofold increase in the immobile E-cadherin fraction (Fig. 5h) , demonstrating that the increase in Rac activation is required for Par3-shRNA-induced inhibition of E-cadherin junction stability. To understand how ErbB2 signalling cooperates with Par3 shRNA to promote unstable E-cadherin junctions and cell invasion, we blocked ErbB2-induced MAPK activation using MEK inhibitors U0126 and PD98059, or AKT using GSK690693 (Fig. 5i) . Suppression of MEK or AKT activity inhibited ErbB2-induced invasion of Par3-shRNA cells (Fig. 5j) . Interestingly, none of these inhibitors restored Par3-shRNA-induced defects in E-cadherin junction turnover (Fig. 5k) .
Loss of Par3 induces changes in actin cytoskeleton organization and ARPC2 localization
The actin cytoskeleton undergoes major changes during E-cadherin junction maturation. As Rac activity is known to regulate actin dynamics 41, 42 by affecting actin nucleators including the Arp2/3 complex, we investigated whether actin cytoskeleton organization or Arp2/3 complex localization is altered in Par3-knockdown cells. In a confluent layer of GFP-shRNA 10A.B2 epithelial cells, F-actin was organized at cell-cell junctions to form a compact cortical actin belt (Fig. 6a, left panel) , whereas Par3-shRNA cells had loosely organized F-actin (Fig. 6a, right panel) . ARPC2 (also known as p34-ARC; ref. 43 ), a component of the Arp2/3 complex was localized to cell-cell junctions in GFP-shRNA cells but was mislocalized throughout the cell in Par3-shRNA cells (Fig. 6b) . ErbB2 activation induced a modest loosening of the cortical actin in GFP-shRNA cells and a severe disruption of cortical actin and ARPC2 localization in Par3-shRNA cells (Fig. 6a,b) . Loss of Par3 induced changes in cortical actin and ARPC2 localization in Eph4, a normal mouse mammary cell line (Fig. 6c) and in the T47D breast cancer cell line ( Supplementary Fig. S5a ), stably expressing Par3 shRNA, demonstrating that the Par3-shRNA-induced changes in cortical actin and ARPC2 localization were not specific for MCF-10A cells.
Interestingly, primary tumour generated from empty-vector-infected NDL tumour cells (Fig. 2d) had well-organized cortical actin and ARPC2 localization to cell-cell junctions, whereas the tumour and metastasis generated from Par3-shRNA-infected cells showed loose cortical actin and mislocalization of ARPC2 from cell-cell junctions ( Fig. 6d and Supplementary Fig. S5b ). In addition, the tumour epithelia in the spontaneous lung metastasis of MMTV-NDL mice had a marked disruption of cortical actin organization and ARPC2 localization when compared with that observed in cells within primary tumours from the same mice ( Supplementary Fig. S5c ). Furthermore, we observe a biochemical interaction between ARPC2 and Par3 by co-immunoprecipitation analysis ( Fig. 6e and Supplementary Fig. S5d ). These observations demonstrate that loss of Par3 relates to disruption of cortical actin and mislocalization of ARPC2 in epithelial cells in culture and in vivo.
Given that Par3-loss-induced cell invasion requires Tiam1, we investigated the role played by Tiam1 on actin organization and ARPC2 localization. Knockdown of Tiam1 in Par3-shRNA cells or inhibition of Tiam1-Rac activation using NSC23766 led to an increase in cortical actin organization ( Fig. 6f and Supplementary  Fig. S5e ). Whereas expression of Par3-FL in Par3-shRNA cells restored cortical actin organization, expression of Par3-C failed to do so (Fig. 6g) . Interestingly, both Par3-FL and Par3-C restored ARPC2 localization to cell-cell junctions (Fig. 6g) , suggesting that ARPC2 localization can be uncoupled from Tiam1-Rac signalling and that cell-cell junction localization of ARPC2 was not sufficient to restore cortical actin organization.
Loss of Par3 promotes aberrant actin and E-cadherin dynamics at cell-cell junctions
The decrease in cell-cell cohesion may be due to aberrant actin and cadherin dynamics at cell-cell contacts. To investigate this directly, we performed time-lapse imaging of cells co-expressing E-cadherin-GFP and red fluorescent protein TagRFP fused to LifeAct, a 17-amino-acid peptide that labels F-actin 44 . In the control cells, E-cadherin (green) co-localized with F-actin (red) to form a continuous, smooth junctional structure of even thickness (Fig. 7a) . During the 10 min of time-lapse imaging, we did not observe any noticeable change in the overall organization of F-actin or E-cadherin (Fig. 7a, upper outlined area) . However, in Par3-shRNA cells F-actin organization was complex with thin actin filaments adjacent to the cortical belt, similar to the structures reported in immature cell-cell contacts. During the 10 min of time-lapse imaging, E-cadherin and F-actin at cell-cell junctions of Par3-shRNA cells were highly dynamic with oscillating protrusions and retractions (Fig. 7a , lower outlined area; see also Supplementary Video S1). Kymograph analysis of LifeAct-TagRFP from representative regions in control and Par3-shRNA cells revealed that the average speed of actin protrusions at cell-cell junctions in Par3-shRNA cells was 4-5-fold higher when compared with that observed in control cells (Fig. 7b,c) . Thus, loss of Par3 promotes dynamic remodelling of F-actin and E-cadherin at cell-cell junctions.
Dysregulation of Par3 in human breast cancer
To understand the relationship between Par3 expression and tumour characteristics in invasive breast cancer (IBC), we analysed formalin-fixed paraffin-embedded tissue samples of human IBCs (n = 98) assembled on tissue microarrays 45 . Par3 expression was evaluated by indirect immunofluorescence microscopy using anti-Par3 antibody. Change in membrane-localized Par3 was studied using the Allred score (total score range 0-8). An Allred score of 3 corresponds to as few as 10% of cells with weak membrane signal and an Allred score 7 indicates strong membrane Par3 in 66% of cells (Fig. 8a) . The level of Par3 membrane localization was significantly decreased in IBCs associated with clinically aggressive prognostic factors, including higher nuclear grade, negative ER status, and positive HER2 status (Supplementary Table S1 ); indicators of poor clinical prognosis. We have also observed Par3 mislocalized in some human breast cancer samples analysed ( Supplementary Fig. S6) ; however, the cause and consequence of Par3 mislocalization are still unclear.
To address whether changes in Par3 expression are associated with breast cancer metastasis, we identified 14 pairs of primary breast tumour (BST) and matched metastasis (MET) from the same patient and analysed them for expression of Par3 by immunohistochemistry and quantified the level of expression using the Allred score. The results demonstrate that eight out of 14 metastases have a decrease in the level of membrane Par3 expression when compared with matched primary tumours (Fig. 8b) , two out of 14 metastases show no change in levels of Par3 (Fig. 8c) , and four out 14 metastases show an increase in the levels of Par3 when compared with the Par3 levels in matched primary tumours (Fig. 8d) . Statistical analysis using a binomial test suggests a significant probability (P = 0.0174) for the BST > MET scenario (Fig. 8b) , but not the other two groups. These observations provide direct evidence to suggest a trend of downregulation of Par3 in the metastases. We acknowledge that analysis of a larger cohort of primary and metastasis samples could provide further insight. However, our present analysis of this 14-matched-pair cohort of samples provides statistically significant evidence in support of our conclusion that downregulation of Par3 is associated with metastasis in breast cancer.
DISCUSSION
We demonstrate that downregulation of Par3 expression is frequently observed in human breast cancer and promotes metastasis of ErbB2-induced mouse mammary tumours. Downregulation of Par3 promoted invasive behaviour of epithelial cells by inducing actin and E-cadherin dynamics at cell-cell contacts and inhibiting cell-cell cohesion in a Tiam1-dependent manner. Thus, we identify the Par3 polarity protein as a metastasis suppressor in breast cancer.
Although ErbB2 is overexpressed in more than 60% of breast cancer patients with ductal carcinoma in situ, only 15% of invasive ductal carcinoma express ErbB2, suggesting that expression of ErbB2 by itself is not sufficient to drive metastatic disease. Consistently, loss of 14-3-3 σ and overexpression of 14-3-3 ζ cooperates with ErbB2 to induce invasion and metastasis in cell culture and animal models of ErbB2-positive breast cancers 46, 47 . 14-3-3 (Par5) interacts with Par3 to regulate cell polarity during early divisions of C. elegans embryos and in mammalian epithelial cells 48, 49 . Our findings, in conjunction with previous reports, identify the Par3-14-3-3 signalling module as an important regulator of metastasis in ErbB2-overexpressing breast cancers.
We find that the aberrant increase in Tiam1-mediated Rac-GTP loading was required for Par3-loss-induced effects on cortical actin and E-cadherin junction dynamics. Although Par3-shRNA cells also show mislocalization of ARPC2, restoring ARPC2 localization to cell-cell junctions was not sufficient to restore cortical actin organization or inhibit invasion. Thus, loss of Par3 promotes spatially dysregulated, Tiam1-mediated, Rac activation, which leads to uncontrolled Arp2/3 activity and actin dynamics. This aberrant actin dynamics probably compromises E-cadherin junctions and decreases cohesion between tumour epithelial cells and promotes metastasis.
We speculate that, in addition to loss of Par3, unregulated activation of Arp2/3 can promote aberrant actin remodelling and compromise cell-cell cohesion to promote metastatic behaviours of epithelial cells. Consistent with this possibility, co-expression of Arp2 and the Arp2/3 activator WAVE2 predicts poor outcome in invasive breast cancers 50 and dysregulation of proteins that regulate actin nucleation is frequently observed in multiple cancers 51 . Elevated expression levels of both Cdc42 and Arp2/3 have been observed in invasive cells 52 . Loss of Arp2/3 inhibitors may also promote aggressive cancer. Consistent with this possibility, the genetic region containing α-catenin, an inhibitor of Arp2/3 (ref. 53) , was deleted in two out of three metastases but retained in the matched primary basal breast cancers 54 . Understanding the mechanisms of actin regulation during tumour progression will provide new insights into tumour cell behaviour.
Recently, much evidence has suggested that the EMT process, typically associated with normal development, may be a critical process in tumour progression 55, 56 . Although we do not observe EMT, a role for partial EMT cannot be ruled out. However, it is also possible that loss of Par3-induced metastasis does not require EMT, which is consistent with a concurrent study demonstrating that loss of Par3 cooperates with the Notch intracellular domain or Ras 61L -induced metastasis to promote metastasis of mammary tumours without showing EMT (ref. 57). Our observations provide a new perspective to our understanding of the cancer metastasis process.
Metastatic tumours are known to have significant evidence for loss of polarity, disordered differentiation and loss of lineage-specific markers in carcinomas. Although these changes can be highly pleomorphic, cells within the primary tumour as well as cells that are migrating away from the primary tumour tend to retain significant epithelial characteristics such as expression of epithelial keratins, mucins and E-cadherin 58 . Although tumour cells that have undergone EMT during metastasis are thought to regain epithelial characteristics by undergoing a mesenchymal to epithelial transition 55 , the molecular mechanisms by which these transitions occur are poorly understood. Our observations of a decrease in cell-cell cohesion and acquisition of a metastatic-epithelial phenotype provide another perspective and identify regulation of E-cadherin junction maturation, changes in cortical actin organization and cell-cell cohesion as mechanisms used by tumour epithelium to metastasize. A deeper and broader understanding of this process will not only identify new predictive biomarkers for tumours with metastatic potential, but also identify new strategies to inhibit metastasis.
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